Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A composition comprising a carrier and, *(I)* a PDE4 inhibitor and *(II)* an anti-cholinergic agent selected from the group consisting of tiotropium, ~~and pharmaceutically acceptable salts, isomers, isotopes, polymorphs, hydrates and solvates thereof,~~ a pharmaceutically acceptable salt of tiotropium, an isomer of tiotropium, an isotope of tiotropium, a polymorph of tiotropium, a hydrate of tiotropium, and a solvate of tiotropium, in an effective therapeutic amount to treat an inflammatory disease or obstructive airways disease.

2. (Original) The composition according to claim 1 wherein said obstructive airways disease is asthma, COPD, or other obstructive airways disease exacerbated by bronchial hyper-reactivity or bronchospasm.

3. (Currently Amended) The composition according to claim 1 wherein said PDE4 inhibitor is a compound of Formula (1.1.1):



(1.1.1)

wherein:

R^1 is –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_2-C_4) alkenyl; phenyl; –$N(CH_3)_2$; (C_3-C_6) cycloalkyl; (C_3-C_6) cycloalkyl–(C_1-C_3) alkyl; or (C_1-C_6) alkylcarbonyl; where said alkyl, phenyl or alkenyl group is substituted by 0 to 2 of –OH, (C_1-C_3) alkyl, or -CF_3, or 0 to 3 of halo;

R^2 and R^3 are each independently selected from the group consisting of: -H; (C_1-C_{14}) alkyl; (C_1-C_7) alkoxy–(C_1-C_7) alkyl; (C_2-C_{14}) alkenyl; (C_3-C_7) cycloalkyl; (C_3-C_7) cycloalkyl–(C_1-C_2) alkyl; a saturated or unsaturated (C_4-C_7) heterocyclic–$(CH_2)_n$ group where n is 0, 1 or 2, containing as the heteroatom one or two ~~of~~ atoms or groups selected from the group consisting of oxygen, sulfur, sulfonyl, nitrogen and NR^4 where R^4 is –H or (C_1-C_4) alkyl; and a group of partial Formula (1.1.2):



(1.1.2)

where

a is an integer from 1 to 5;

b and c are 0 or 1;

R^5 is –H; –OH; (C_1-C_5) alkyl; (C_2-C_5) alkenyl; (C_1-C_5) alkoxy; (C_3-C_6) cycloalkoxy; halo; –CF_3; –CO_2R^6; –$CONR^6R^7$; –NR^6R^7; –NO_2; or –$SO_2NR^6R^7$ where R^6 and R^7 are each independently –H; or (C_1-C_4) alkyl;

Z is –O–; –S–; –SO_2–; –C(=O)–; or –$N(R^8)$– where R^8 is –H; or (C_1-C_4) alkyl; and

Y is (C_1-C_5) alkylene; or (C_2-C_6) alkenylene~~;~~ each substituted by 0 to 2 of (C_1-C_7) alkyl or (C_3-C_7) cycloalkyl; and

wherein each of said above-recited alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic groups is substituted by 0 to 14~~, preferably 0 to 5,~~ of (C_1-C_2) alkyl, CF_3, or halo; and

R^9 and R^{10} are each independently selected from the group consisting of –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_6-C_{10}) aryl; and (C_6-C_{10}) aryloxy;

or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) The composition according to claim 3 wherein the PDE4 inhibitor ~~comprises a member~~ is selected from the group consisting of:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-α]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine; and

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine.

5. (Currently Amended) The composition according to claim 3 wherein the PDE4 inhibitor is ~~9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine~~ 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine or 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(*tert*-butyl)-9*H*-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridine.

6. (Currently Amended) The composition according to claim 1 wherein the anti-cholinergic agent ~~comprises a member~~ is ~~selected from the group consisting of tiotropium, and pharmaceutically acceptable salts, isomers, isotopes, polymorphs, hydrates and solvates thereof, and~~ a tiotropium compound of Formula (2.1.1):



(2.1.1)

wherein X^- is a physiologically acceptable anion.

7. (Original) The composition according to claim 6 wherein said physiologically acceptable anion, X^-, is selected from the group consisting of fluoride, F^-; chloride, Cl^-; bromide, Br^-; iodide, I^-; methanesulfonate, $CH_3S(=O)_2O^-$; ethanesulfonate, $CH_3CH_2S(=O)_2O^-$; methylsulfate, $CH_3OS(=O)_2O^-$; benzene sulfonate, $C_6H_5S(=O)_2O^-$; *p*-toluenesulfonate, and 4-CH_3-$C_6H_5S(=O)_2O^-$.

8. (Original) The composition according to claim 7 wherein the physiologically acceptable anion, X^-, is bromide, Br^-.

9. (Currently Amended) The composition according to claim 6 wherein the anti-cholinergic agent comprises a 3-α tiotropium compound.

10. (Currently Amended) The composition according to ~~claim 9~~ claim 1 wherein the anti-cholinergic agent is selected from the group consisting of tiotropium bromide and (1α, 2β, 4β, 5β, 7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.$0^{2,4}$]nonane bromide, represented by Formula (2.1.2) or Formula (2.1.3):



(2.1.2)



(2.1.3)

11. (Withdrawn-Currently Amended) A method for the treatment of an obstructive airways or inflammatory disease, comprising administering to a mammal *(I)* a PDE4 inhibitor and, *(II)* an anti-cholinergic agent ~~comprising a member~~ selected from the group consisting of tiotropium ~~and a pharmaceutically acceptable salts, isomers, isotopes, polymorphs, hydrates and solvates thereof~~, a pharmaceutically acceptable salt of tiotropium, an isomer of tiotropium, an isotope of tiotropium, a polymorph of tiotropium, a hydrate of tiotropium, and a solvate of tiotropium, in a therapeutically effective amount to treat the disease when administered by inhalation.

12. (Withdrawn) The method according to claim 11 wherein the obstructive airways disease is asthma, COPD, or other obstructive airways disease exacerbated by bronchial hyper-reactivity or bronchospasm.

13. (Withdrawn) The method of treatment according to claim 12 wherein the mammal is a human being.

14. (Withdrawn) The method according to claim 11 wherein the administration comprises simultaneous or sequential delivery of the PDE4 inhibitor and anti-cholinergic agent in the form of an aerosol or dry powder.

15. (Withdrawn-Currently Amended) The method according to claim 11 wherein the PDE4 inhibitor comprises a compound of Formula (1.1.1):



(1.1.1)

wherein:

R^1 is –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_2-C_4) alkenyl; phenyl; –$N(CH_3)_2$; (C_3-C_6) cycloalkyl; (C_3-C_6) cycloalkyl–(C_1-C_3) alkyl; or (C_1-C_6) alkylcarbonyl; where said alkyl, phenyl or alkenyl group is substituted by 0 to 2 of –OH, (C_1-C_3) alkyl, or -CF_3, or 0 to 3 of halo;

R^2 and R^3 are each independently selected from the group consisting of: -H; (C_1-C_{14}) alkyl; (C_1-C_7) alkoxy–(C_1-C_7) alkyl; (C_2-C_{14}) alkenyl; (C_3-C_7) cycloalkyl;

(C_3-C_7) cycloalkyl–(C_1-C_2) alkyl; a saturated or unsaturated (C_4-C_7) heterocyclic–$(CH_2)_n$ group where n is 0, 1 or 2, containing as the heteroatom one or two ~~of~~ atoms or groups selected from the group consisting of oxygen, sulfur, sulfonyl, nitrogen and NR^4 where R^4 is –H or (C_1-C_4) alkyl; and a group of partial Formula (1.1.2):



(1.1.2)

where

a is an integer from 1 to 5;

b and c are 0 or 1;

R^5 is –H; –OH; (C_1-C_5) alkyl; (C_2-C_5) alkenyl; (C_1-C_5) alkoxy; (C_3-C_6) cycloalkoxy; halo; $–CF_3$; $–CO_2R^6$; $–CONR^6R^7$; $–NR^6R^7$; $–NO_2$; or $–SO_2NR^6R^7$ where R^6 and R^7 are each independently –H; or (C_1-C_4) alkyl;

Z is –O–; –S–; $–SO_2–$; –C(=O)–; or $–N(R^8)–$ where R^8 is –H; or (C_1-C_4) alkyl; and

Y is (C_1-C_5) alkylene; or (C_2-C_6) alkenylene~~;~~ each substituted by 0 to 2 of (C_1-C_7) alkyl or (C_3-C_7) cycloalkyl; and

wherein each of said above-recited alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic groups is substituted by 0 to 14~~, preferably 0 to 5,~~ of (C_1-C_2) alkyl, CF_3, or halo; and

R^9 and R^{10} are each independently selected from the group consisting of –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_6-C_{10}) aryl; and (C_6-C_{10}) aryloxy;

or a pharmaceutically acceptable salt thereof.

16. (Withdrawn-Currently Amended) The method according to claim 15 wherein the PDE4 inhibitor ~~comprises a member~~ is selected from the group consisting of:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-α]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine; and

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine.

17. (Withdrawn-Currently Amended) The method according to claim 11 wherein the anti-cholinergic agent ~~comprises a member selected from the group consisting of tiotropium, and pharmaceutically acceptable salts, isomers, isotopes, polymorphs, hydrates and solvates thereof, and~~ is a tiotropium compound of Formula (2.1.1):



(2.1.1)

wherein X^- is a physiologically acceptable anion.

18. (Withdrawn) The method according to claim 17 wherein the physiologically acceptable anion, X^-, is bromide, Br^-.

19. (Withdrawn-Currently Amended) A method of treatment according to ~~claim 18~~ claim 11 wherein the anti-cholinergic agent ~~comprises a~~ is selected from the group consisting of tiotropium bromide and (1α, 2β, 4β, 5β, 7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.$0^{2,4}$]nonane bromide, represented by Formula (2.1.2) or Formula (2.1.3):



(2.1.2)



(2.1.3) .

20. (Original) The composition according to claim 1 comprising a carrier, (I) a PDE4 inhibitor and, (II) an anticholinergic agent, in a form suitable for administration by inhalation.

21. (Currently Amended) The composition according to claim 20 wherein the form suitable for administration by inhalation comprises simultaneous or ~~sequential delivery of~~ sequentially deliverable forms of components (I) and (II) in the form of an aerosol or dry powder.

22. (Currently Amended) The composition according to claim 20 wherein the PDE4 inhibitor comprises a compound of formula (1.1.1)



(1.1.1)

wherein:

R^1 is –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_2-C_4) alkenyl; phenyl; –$N(CH_3)_2$; (C_3-C_6) cycloalkyl; (C_3-C_6) cycloalkyl–(C_1-C_3) alkyl; or (C_1-C_6) alkylcarbonyl; where said alkyl, phenyl or alkenyl group is substituted by 0 to 2 of –OH, (C_1-C_3) alkyl, or -CF_3, or 0 to 3 of halo;

R^2 and R^3 are each independently selected from the group consisting of: -H; (C_1-C_{14}) alkyl; (C_1-C_7) alkoxy–(C_1-C_7) alkyl; (C_2-C_{14}) alkenyl; (C_3-C_7) cycloalkyl; (C_3-C_7) cycloalkyl–(C_1-C_2) alkyl; a saturated or unsaturated (C_4-C_7) heterocyclic–$(CH_2)_n$ group where n is 0, 1 or 2, containing as the heteroatom one or two ~~of~~ atoms or groups

selected from the group consisting of oxygen, sulfur, sulfonyl, nitrogen and NR^4 where R^4 is –H or (C_1-C_4) alkyl; and a group of partial Formula (1.1.2):



(1.1.2)

where

a is an integer from 1 to 5;

b and c are 0 or 1;

R^5 is –H; –OH; (C_1-C_5) alkyl; (C_2-C_5) alkenyl; (C_1-C_5) alkoxy; (C_3-C_6) cycloalkoxy; halo; $–CF_3$; $–CO_2R^6$; $–CONR^6R^7$; $–NR^6R^7$; $–NO_2$; or $–SO_2NR^6R^7$ where R^6 and R^7 are each independently –H; or (C_1-C_4) alkyl;

Z is –O–; –S–; $–SO_2–$; –C(=O)–; or $–N(R^8)–$ where R^8 is –H; or (C_1-C_4) alkyl; and

Y is (C_1-C_5) alkylene; or (C_2-C_6) alkenylene~~;~~ each substituted by 0 to 2 of (C_1-C_7) alkyl or (C_3-C_7) cycloalkyl; and

wherein each of said above-recited alkyl, alkenyl, cycloalkyl, alkoxyalkyl or heterocyclic groups is substituted by 0 to 14~~, preferably 0 to 5,~~ of (C_1-C_2) alkyl, CF_3, or halo; and

R^9 and R^{10} are each independently selected from the group consisting of –H; (C_1-C_6) alkyl; (C_1-C_6) alkoxy; (C_6-C_{10}) aryl; and (C_6-C_{10}) aryloxy;

or a pharmaceutically acceptable salt thereof.

23. (Original) The composition according to claim 22 wherein the PDE4 inhibitor comprises a compound selected from the group consisting of

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-α]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine; and

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine.

24. (Original) The composition according to claim 20 wherein the anticholinergic agent comprises a compound of Formula (2.1.1)



(2.1.1)

wherein X^- is a physiologically acceptable anion.

25. (Original) The composition according to claim 24 wherein said physiologically acceptable anion, X^-, is selected from the group consisting of fluoride, F^-; chloride, Cl^-; bromide, Br^-; iodide, I^-; methanesulfonate, $CH_3S(=O)_2O^-$; ethanesulfonate,

$CH_3CH_2S(=O)_2O^-$; methylsulfate, $CH_3OS(=O)_2O^-$; benzene sulfonate, $C_6H_5S(=O)_2O^-$; *p*-toluenesulfonate, and 4-CH_3-$C_6H_5S(=O)_2O^-$.

26. (Original) The composition according to claim 25 wherein said physiologically acceptable anion, X^-, is bromide, Br^-.

27. (Currently Amended) The composition according to claim 24 wherein the anticholinergic agent comprises a 3-α tiotropium compound.

28. (Currently Amended) The composition according to ~~claim 27~~ claim 24 wherein the anticholinergic agent is selected from the group consisting of tiotropium bromide and (1α, 2β, 4β, 5β, 7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa--9-azoniatricyclo[3.3.1.$0^{2,4}$]non-ane bromide, represented by Formula (2.1.2):



(2.1.2) .

29. (Currently Amended) A package containing the composition according to claim 20 capable of insertion into a device for simultaneous or sequential delivery of the composition in the form of an aerosol or dry powder.

30. (Original) The package according to claim 29 wherein the composition comprises a PDE4 inhibitor selected from the group consisting of:

9-cyclopentyl-5,6-dihydro-7-ethyl-3-phenyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopenyl-5,6-dihydro-7-ethyl-3-(furan-2-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(4-pyridyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(3-thienyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-benzyl-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-propyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3,9-dicyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

3-(*tert*-butyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-methoxyphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9*H*-pyrazolo[3,4-*c*]1,2,4-triazolo[4,3-α]pyridine;

3-(2-chlorophenyl)-9-cyclopentyl-5,6-dihydro-7-ethyl-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-iodophenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine;

9-cyclopentyl-5,6-dihydro-7-ethyl-3-(2-trifluoromethylphenyl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine; and

5,6-dihydro-7-ethyl-9-(4-fluorophenyl)-3-(1-methylcyclohex-1-yl)-9*H*-pyrazolo[3,4-*c*]-1,2,4-triazolo[4,3-α]pyridine.

31. (Original) The package according to claim 29 wherein the composition comprises an anticholinergic agent of Formula (2.1.1)



(2.1.1)

wherein X^- is a physiologically acceptable anion.

32. (Original) The package according to claim 31 wherein the physiologically acceptable anion, X^-, is bromide, Br^-.

33. (Currently Amended) The package according to claim 29 wherein the composition comprises an anticholinergic agent selected from the group consisting of tiotropium bromide and (1α, 2β, 4β, 5β, 7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa--9-azoniatricyclo[3.3.1.$0^{2,4}$]non-ane bromide, represented by Formula (2.1.2):



(2.1.2).

34. (Original) The package according to claim 29 wherein said device is a metered dose inhaler or a dry powder inhaler.